India: The Opportunity to be a Global Leader in Fatty Liver Disease
- India witnesses a high prevalence of metabolic-associated steatotic liver disease (MASLD), and thus holds the opportunity to be the leader.
- Education and awareness about the disease are crucial both among physicians and the public. INASL Guidance paper and CMEs for the physicians are crucial in this regard. For patient and community perspective ROCCO is crucial.
- Treatment with saroglitazar needs proper guidance for usage.
- National policies like NPCDCS should integrate nonalcoholic fatty liver disease (NAFLD).
Dr. Ajay Kumar Duseja
Dr Ajay Kumar Duseja is presently working as Professor in the department of Hepatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. He did his MBBS in 1988, MD (Internal Medicine) in 1992 and DM (Gastroenterology) from PGIMER, Chandigarh in 1996. For last 22 years, he is working as Faculty with focused research in the field of Hepatology (See Academic Qualifications). He is Fellow of National Academy of Medical Sciences (FAMS), Fellow of American Association for the Study of Liver Diseases (FAASLD), Fellow of American College of Gastroenterology (FACG) and Fellow of the Society of GI Endoscopy of India (FSGEI) (See Academic Qualifications).
More FAQs by Dr. Ajay Kumar Duseja
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please login to comment on this article